3 Bioscience Park Dr.
About Codagenix, Inc.
Codagenix is a clinical stage, venture and public-sector-funded small business that is using our synthetic biology-based vaccine design platform “SAVE” to construct prophylactic viral vaccines and oncolytic agents. All viruses, whether Zika or influenza, uses the host cell ribosome to translate their genome and synthesize their proteins. SAVE is a computer algorithm that re-codes and “de-optimizes” viral genes – in turn putting the wild-type viral genes in a “language” read slowly by the mammalian host ribosome. De-optimization results in a vast reduction of pathogenesis, yet induction of a potent immune response given the presentation of ALL, perfectly matched antigens of the target. This platform has universal applications to the re-design of viral genomes.
Codagenix’s lead program is a live-attenuated, universal Influenza vaccine that has demonstrated safety and broad immunogenicity in a Phase I clinical trial. Using SAVE, Codagenix is developing a pipeline of live-attenuated vaccines against other targets including: RSV (Phase I Q1-2019), Zika (Phase I Q1-2019), and Dengue as well as rationally designed oncolytic candidates against Melanoma, Triple-Negative Breast Cancer, and Neuroblastoma.
Codagenix also has an established partnership in the agricultural space - designing and co-developing SAVE-deoptimized vaccines for swine, canine, bovine, and other markets.
13 articles with Codagenix, Inc.
Intranasal COVID-19 vaccine demonstrates single-dose efficacy in preclinical studies, in parallel with achievement of Phase 1 clinical milestone
Codagenix Inc., a clinical-stage synthetic biology company pioneering a novel platform for vaccines and oncolytic virus therapies, today announced preclinical data published in the Proceedings of the National Academy of Science (PNAS) supporting the potential safety and efficacy of COVI-VAC, the company's intranasal live-attenuated COVID-19 vaccine
Codagenix Appoints Johanna Kaufmann, Ph.D., Executive Vice President, Oncology to Lead Customization of Oncolytic Viruses for Solid Tumors
Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies for cancer, today announced the appointment of innovative oncology leader Johanna Kaufmann, Ph.D., as Executive Vice President, Oncology.
Ms. Maldonado to Oversee Manufacturing Development of Codagenix's Vaccines as Clinical Trials for COVID-19, RSV and Flu Progress
With billions invested in R&D over the past year to find vaccines and therapies for the novel coronavirus, a few select life sciences companies and academic institutions are working on the hypothesis that intranasal vaccines and therapies could be key to stopping COVID-19 in its tracks, and provi...
Codagenix's CEO to Present Update on COVI-VAC During New York Academy of Sciences Event, "Quest for a COVID-19 Vaccine"
Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, announced that CEO J. Robert Coleman, Ph.D., M.B.A., will present an update on COVI-VAC during the New York Academy of Science's (NYAS) two-day webinar event, "Quest for a COVID-19 Vaccine,
Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, announced the issuance of a patent for a vaccine focused on human codon-deoptimized respiratory syncytial viruses vaccine.
Codagenix Inc. Completes Dosing for Phase 1 Trial of Live-Attenuated, Intranasal Vaccine for Respiratory Syncytial Virus (RSV)
Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, announced today the completion of dosing in a Phase 1 clinical trial of its live attenuated CodaVax™-RSV vaccine, an intranasally-administered vaccine for the prevention of respiratory syncytial virus (RSV).
Former Merck Executive and Vaccine Industry Leader to Drive Development Opportunities for Codagenix's Diverse Pipeline, Including Vaccine Candidates for SARS-CoV-2 and RSV
Serum Institute of India Initiates Manufacturing of Codagenix's Intranasal Live-Attenuated COVID-19 Vaccine Candidate
- Phase 1 clinical trial of CDX-005 expected to initiate prior to year-end 2020 - Serum Institute to ramp-up manufacturing for large-scale safety and efficacy studies and to meet global vaccine supply requirements [22-September-2020] FARMINGDALE, N.Y. , Sept. 22, 2020 /PRNewswire/ -- Codagenix, Inc., a clinical-stage biotechnology company developing pr
The 11-person team at Codagenix may be tiny, but it has big plans for the company’s new COVID-19 vaccine.
Codagenix Announces the Synthesis and Preliminary Safety of Scalable, Live-attenuated Vaccine Candidate Against COVID-19
Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the successful synthesis of a readily-scalable live-attenuated vaccine candidate against COVID-19. The vaccine, CDX-005, is currently undergoing safety and efficacy studies in animals and appears m
Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19
FARMINGDALE, N.Y. , Feb. 13, 2020 /PRNewswire/ -- Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced a collaboration with the Serum Institute of India to rapidly co-develop a live-attenuated vaccine against the emergent coronavirus. There are no licensed vaccines or therapeutics for this nov
Codagenix Raises $20 Million in Series B Funding for Continued Development of RSV, Influenza and Oncolytic Virus Products
Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the closing of a $20 million Series B investment round.